Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenofovir alafenamide - Gilead Sciences

Next Previous
Drug Profile

Tenofovir alafenamide - Gilead Sciences

Alternative Names: GS-7340; GS-7340-02; GS-7340-03; TAF; Tenofovir alafenamide fumarate; Vemlidy

Latest Information Update: 15 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; University Hospital Inselspital; University of California
  • Class Amines; Antiretrovirals; Antivirals; Phosphorus compounds; Propionates; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B
  • Phase III HIV-1 infections
  • Phase II HIV infections

Most Recent Events

  • 15 Jun 2026 Gilead Sciences plans a phase II trial for Epstein-Barr virus infections (In volunteers) in Norway (PO, Tablet)(CTIS2025-522781-77-01) (EudraCT2025-522781-77-01)
  • 01 Apr 2024 Launched for Hepatitis B (In children) in USA (PO)
  • 28 Mar 2024 Registered for Hepatitis B (In children) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top